Cellid Co., Ltd. Logo

Cellid Co., Ltd.

Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.

299660 | KO

Overview

Corporate Details

ISIN(s):
KR7299660001
LEI:
Country:
South Korea
Address:
서울시 관악구 관악로 1 서울대학교 142동 5층, 서울시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellid Co., Ltd. is a research and development-focused biotechnology company specializing in immunotherapeutic vaccines for cancer and infectious diseases. The company's core business is centered on its proprietary technology platforms. Its key offering, CeliVax, is an anti-cancer immunotherapeutic vaccine platform that utilizes a patient's own B cells and monocytes, designed to be applicable to any cancer with identified antigens. In addition, Cellid has developed an adenovirus vector-based platform for creating preventive vaccines against infectious diseases, notably used in the development of a COVID-19 vaccine. The company's pipeline is focused on leveraging these technologies to address significant unmet medical needs in oncology and virology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 8.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1015.8 KB
2025-08-12 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구)
Korean 7.0 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 28.4 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 27.6 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 26.2 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB

Automate Your Workflow. Get a real-time feed of all Cellid Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellid Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellid Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.